Ultragenyx

RARE NASDAQ
62.47
+0.01
+0.02%
Opening 10:53 07/19 EDT
Open
62.58
Prev Close
62.46
High
63.21
Low
61.87
Volume
102.57K
Avg Vol (3M)
418.55K
52 Week High
90.98
52 Week Low
37.44
% Turnover
0.18%
Market Cap
3.59B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ultragenyx RARE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
MORE >

Recently

Name
Price
%Change